Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily
- PMID: 32369610
- DOI: 10.1111/bjh.16783
Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily
Keywords: COVID-19; complement; complement inhibition; thrombotic microangiopathy.
References
-
- Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation. 2020. [Epub ahead of print]
-
- Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38.
-
- Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Investigat. 2020;130(5):2152-63.
-
- Chaturvedi S, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135:239-51.
-
- Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol. 2020. [Epub ahead of print]
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources